Extended Data Fig. 8: Univariate and multivariate analysis of lower tertile versus upper 2 tertiles of serum biomarker alterations by Gleason grade group decline ≥2 or by PSA0 response at 1 year.
From: Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
Serum biomarkers assessed in n = 64 blood samples from n = 32 patients. (a-c) By Gleason grade group decline ≥2: (a) Gleason grade group ≥ 2 decline by biomarker and percentile. (b) Unadjusted hazard ratio and 95% confidence interval shown for each biomarker. (c) Adjusted hazard ratio and 95% confidence interval by age. (d-f) By PSA0 response at 1 year: (d) PSA0 responders at 1 year by biomarker and percentile. (e) Unadjusted hazard ratio and 95% confidence interval shown for each biomarker. (f) Adjusted hazard ratio and 95% confidence interval by age.
